The effect of platinum-based chemotherapy (Chem.)and second- or multiple- line immune checkpoint PD-1 blocking therapy by Nivolumab or Pembrolizumab (ICI) was assayed in the peripheral blood of non-small cell lung cancer (NSCLC) patients. This evidence concerns the gene RPL17 and non-small cell lung carcinoma.